Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient

Stem Cell Reviews and Reports

Volumn 13, Issue 5, 2017, Pages 686-698

  Coatti, Giuliana Castello ^a   Frangini, Miriam ^b   Valadares, Marcos C ^a   Gomes, Juliana Plat ^a   Lima, Natalia O ^a   Cavaçana, Natale ^a   Assoni, Amanda F ^a   Pelatti, Mayra V ^a   Birbrair, Alexander ^c,d   de Lima, Antonio Carlos Pedroso ^a   Singer, Julio M ^a   Rocha, Francisco Marcelo M ^a   Da Silva, Giovani Loiola ^a   Mantovani, Mario Sergio ^e   Macedo Souza, Lucia Inês ^a   Ferrari, Merari F R ^a   Zatz, Mayana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Amyotrophic lateral sclerosis; IPSCs; Mesenchymal stromal cells; Motor neurons; Pericytes; SOD1 mice

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; ENDOGLIN; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICROSOMAL AMINOPEPTIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR C; RNA BINDING PROTEIN FUS; THY 1 ANTIGEN; FUS PROTEIN, HUMAN; SOD1 PROTEIN, MOUSE;

ADIPOSE TISSUE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PHAGOCYTOSIS; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MESENCHYMAL STROMA CELL; MOUSE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NERVE CELL; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE STRESS; PERICYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; ANIMAL; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN STEM; CYTOLOGY; DEFICIENCY; DISEASE MODEL; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MORTALITY; MOTONEURON; MUTATION; PATHOLOGY; SPINAL CORD; SURVIVAL ANALYSIS; TRANSGENIC MOUSE; TRANSPLANTATION;

ADIPOSE TISSUE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN STEM; CATALASE; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUTATION; PERICYTES; RNA-BINDING PROTEIN FUS; SPINAL CORD; SUPEROXIDE DISMUTASE-1; SURVIVAL ANALYSIS;

EID: 85023776723     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-017-9752-2     Document Type: Article

References (66)

1. Goodall, E. F., & Morrison, K. E. (2006). Amyotrophic lateral sclerosis (motor neuron disease): Proposed mechanisms and pathways to treatment. Expert Reviews in Molecular Medicine. doi:10.1111/j.1467-9639.2006.00001.x.
2. Guégan, C., & Przedborski, S. (2003). Programmed cell death in amyotrophic lateral sclerosis. Journal of Clinical Investigation. doi:10.1172/JCI200317610.
3. Pasinelli, P., & Brown, R. H. (2006). Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nature Reviews. Neuroscience, 7, 710–723. doi:10.1038/nrn1971.
4. Proctor, E. A., Fee, L., Tao, Y., Redler, R. L., Fay, J. M., Zhang, Y., et al. (2015). Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 113(3), 614–619. doi:10.1073/pnas.1516725113.
5. Bensimon, G., Lacomblez, L., & Meininger, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. The New England journal of medicine, 330. doi:10.1056/NEJM199403033300901.
6. Miller, R. G., Mitchell, J. D., Lyon, M., & Moore, D. H. (2007). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001447.pub2.
7. Mitchell, J. D., & Borasio, G. D. (2007). Amyotrophic lateral sclerosis. Lancet, 369, 2031–2041. doi:10.1016/S0140-6736(07)60944-1.
8. Coatti, G. C., Beccari, M. S., Olávio, T. R., Mitne-Neto, M., Okamoto, O. K., & Zatz, M. (2015). Stem cells for amyotrophic lateral sclerosis modeling and therapy: Myth or fact? Cytometry Part A, 87(3), 197–211. doi:10.1002/cyto.a.22630.
9. Dellavalle, A., Sampaolesi, M., Tonlorenzi, R., Tagliafico, E., Sacchetti, B., Perani, L., et al. (2007). Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology, 9(3), 255–267. doi:10.1038/ncb1542.
10. Valadares, M. C., Gomes, J. P., Castello, G., Assoni, A., Pellati, M., Bueno, C., et al. (2014). Human adipose tissue derived Pericytes increase life span in Utrn (tm1Ked) Dmd (mdx) /J mice. Stem cell reviews. doi:10.1007/s12015-014-9537-9.
11. Chen, C.-W., Okada, M., Proto, J. D., Gao, X., Sekiya, N., Beckman, S. A., et al. (2013). Human pericytes for ischemic heart repair. Stem cells (Dayton, Ohio), 31(2), 305–316. doi:10.1002/stem.1285.
12. Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Mintz, A., & Delbono, O. (2014). Pericytes: Multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle. Frontiers in Aging Neuroscience, 6, 245. doi:10.3389/fnagi.2014.00245.
13. Corselli, M., Chen, C.-W., Crisan, M., Lazzari, L., & Péault, B. (2010). Perivascular ancestors of adult multipotent stem cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(6), 1104–1109. doi:10.1161/ATVBAHA.109.191643.
14. Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3(3), 301–313. doi:10.1016/j.stem.2008.07.003.
15. Caplan, A. I., & Sorrell, J. M. (2015). The MSC curtain that stops the immune system. Immunology Letters, 168(2), 136–139. doi:10.1016/j.imlet.2015.06.005.
16. Winkler, E. A, Bell, R. D., & Zlokovic, B. V. (2011). Central nervous system pericytes in health and disease. Nature Neuroscience, 14(11), 1398–1405. doi:10.1038/nn.2946.
17. Winkler, E. A., Sengillo, J. D., Sagare, A. P., Zhao, Z., Ma, Q., Zuniga, E., et al. (2014). Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proceedings of the National Academy of Sciences of the United States of America, 111(11), E1035–E1042. doi:10.1073/pnas.1401595111.
18. Winkler, E. A., Sengillo, J. D., Sullivan, J. S., Henkel, J. S., Appel, S. H., & Zlokovic, B. V. (2013). Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathologica, 125(1), 111–120. doi:10.1007/s00401-012-1039-8.
19. Assoni, A., Coatti, G., Valadares, M. C., Beccari, M., Gomes, J., Pelatti, M., … Zatz, M. (2016). Different donors mesenchymal stromal cells Secretomes reveal heterogeneous profile of relevance for therapeutic use. Stem Cells and Development, scd.2016.0218. doi:10.1089/scd.2016.0218.
20. Ray, A., & Dittel, B. N. (2010). Isolation of mouse peritoneal cavity cells. Journal of visualized experiments: JoVE. doi:10.3791/1488.
21. Gurney, M. E., Pu, H., Chiu, A. Y., Canto, M. C. D., Polchow, C. Y., Alexander, D. D., et al. (1994). Motor neuron degeneration in mice that express a human cu, Zn superoxide dismutase mutation. Science, 264(18), 1–4.
22. Barnéoud, P., Lolivier, J., Sanger, D. J., Scatton, B., & Moser, P. (1997). Quantitative motor assessment in FALS mice: A longitudinal study. Neuroreport, 8(13), 2861–5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9376520.
23. Doble, A., & Kennel, P. (2000). Animal models of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 1(5), 301–312. doi:10.1080/146608200300079545.
24. Pfohl, S. R., Halicek, M. T., & Mitchell, C. S. (2015). Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: A meta-analysis. Journal of Neuromuscular Diseases, 2, 137–150. doi:10.3233/JND-140068.
25. Heiman-Patterson, T. D., Deitch, J. S., Blankenhorn, E. P., Erwin, K. L., Perreault, M. J., Alexander, B. K., et al. (2005). Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. Journal of the Neurological Sciences, 236(1–2), 1–7. doi:10.1016/j.jns.2005.02.006.
26. McCombe, P. A., & Henderson, R. D. (2010). Effects of gender in amyotrophic lateral sclerosis. Gender Medicine, 7(6), 557–570. doi:10.1016/j.genm.2010.11.010.
27. Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., et al. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 9(1), 4–15. doi:10.1080/17482960701856300.
28. Weydt, P., Hong, S. Y., Kliot, M., & Möller, T. (2003). Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport, 14(7), 1051–1054. doi:10.1097/01.wnr.0000073685.00308.89.
29. Liscic, R. M., & Breljak, D. (2011). Molecular basis of amyotrophic lateral sclerosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(2), 370–372. doi:10.1016/j.pnpbp.2010.07.017.
30. Marchetto, M. C. N. N., Carromeu, C., Acab, A., Yu, D., Yeo, G. W., Mu, Y., et al. (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell, 143(4), 527–539. doi:10.1016/j.cell.2010.10.016.
31. Melo, U. S., Macedo-Souza, L. I., Figueiredo, T., Muotri, A. R., Gleeson, J. G., Coux, G., … Santos, S. (2015). Overexpression of KLC2 due to a homozygous deletion in the non-coding region causes SPOAN syndrome. Human Molecular Genetics, 24(24), ddv388. doi:10.1093/hmg/ddv388.
32. Mitne-Neto, M., Machado-Costa, M., Marchetto, M. C. N. M., Bengtson, M. H. M., Joazeiro, C. C. A., Tsuda, H., et al. (2011). Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Human Molecular Genetics, 20(18), 3642–3652.
33. Aranda, P. S., LaJoie, D. M., & Jorcyk, C. L. (2013). Bleach gel: A simple agarose gel for analyzing RNA quality. Electrophoresis, 33(2), 366–369. doi:10.1002/elps.201100335.Bleach.
34. Pfaffl, M. (2006). Relative quantification. In T. Dorak (Ed.), Real-time PCR (1st ed., pp. 63–82). International University Line.
35. Collett, D. (2003). Modelling survival data in medical research.
36. Cox, D. R. (1972). Regression models and life tables. Journal of the Royal Statistical Society. Series B (Methodological), 34(2), 187–220.
37. Singer, J. M., & Andrade, D. F. (2000). Analysis of longitudinal data. In P. K. Sen & C. R. Rao (Eds.), Handbook of statistics, volume 18: Bio-environmental and public health statistics (pp. 115–160). Amsterdam: North Holland.
38. Muggeo, V. M. R. (2003). Estimating regression models with unknown break-points. Statistics in Medicine, 22(19), 3055–3071. doi:10.1002/sim.1545.
39. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315–317. doi:10.1080/14653240600855905.
40. Alves, C. J., de Santana, L. P., dos Santos, A. J. D., de Oliveira, G. P., Duobles, T., Scorisa, J. M., et al. (2011). Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Research, 1394, 90–104. doi:10.1016/j.brainres.2011.02.060.
41. Peron, J. P. S., Jazedje, T., Brandão, W. N., Perin, P. M., Maluf, M., Evangelista, L. P., et al. (2012). Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice. Stem Cell Reviews, 8(3), 940–952. doi:10.1007/s12015-011-9338-3.
42. Ohshima, M., Taguchi, A., Tsuda, H., Sato, Y., Yamahara, K., Harada-Shiba, M., et al. (2014). Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain & Development, 5–7. doi:10.1016/j.braindev.2014.06.010.
43. James, A. W., Zara, J. N., Zhang, X., Askarinam, A., Goyal, R., Chiang, M., et al. (2012). Perivascular stem cells: A prospectively purified mesenchymal stem cell population for bone tissue engineering. Stem Cells Translational Medicine, 1(6), 510–519. doi:10.5966/sctm.2012-0002.
44. Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Enikolopov, G. N., Mintz, A., & Delbono, O. (2013). Role of pericytes in skeletal muscle regeneration and fat accumulation. Stem Cells and Development, 22(16), 2298–2314. doi:10.1089/scd.2012.0647.
45. Starling, A., Rocco, P., Passos-Bueno, M. R., Hazan, J., Marie, S. K., & Zatz, M. (2002). Autosomal dominant (AD) pure spastic paraplegia (HSP) linked to locus SPG4 affects almost exclusively males in a large pedigree. Journal of medical genetics. doi:10.1136/jmg.39.12.e77.
46. Tonini, M. M. O., Pavanello, R. C. M., Gurgel-Giannetti, J., Lemmers, R. J., van der Maarel, S. M., Frants, R. R., & Zatz, M. (2004). Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more severe phenotype. Journal of Medical Genetics, 41(2), e17 Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1735661&tool=pmcentrez&rendertype=abstract.
47. de Paula, F., Vainzof, M., Passos-Bueno, M. R., de Cássia, M., Pavanello, R., Matioli, S. R., VB Anderson, L., et al. (2002). Clinical variability in calpainopathy: What makes the difference? European journal of human genetics: EJHG, 10(12), 825–832. doi:10.1038/sj.ejhg.5200888.
48. Prockop, D. J., & Youn Oh, J. (2012). Mesenchymal stem/stromal cells (MSCs): Role as guardians of inflammation. Molecular Therapy, 20(1), 14–20. doi:10.1038/mt.2011.211.
49. Kota, D. J., DiCarlo, B., Hetz, R. A., Smith, P., Cox, C. S., & Olson, S. D. (2014). Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms. Scientific Reports, 4, 4565. doi:10.1038/srep04565.
50. Waterman, R. S., Henkle, S. L., & Betancourt, A. M. (2012). Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PloS One, 7(9), e45590. doi:10.1371/journal.pone.0045590.
51. Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010). A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PloS One, 5(4), e10088. doi:10.1371/journal.pone.0010088.
52. Kyurkchiev, D., Bochev, I., Ivanova-Todorova, E., Mourdjeva, M., Oreshkova, T., Belemezova, K., & Kyurkchiev, S. (2014). Secretion of immunoregulatory cytokines by mesenchymal stem cells. World journal of stem cells, 6(5), 552–570. doi:10.4252/wjsc.v6.i5.552.
53. Admyre, C., Axelsson, L.-G., von Stein, O., & Zargari, A. (2015). Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B 4 receptors. Immunology, 144(2), 206–217. doi:10.1111/imm.12368.
54. Shibata, N., Nagai, R., Uchida, K., Horiuchi, S., Yamada, S., Hirano, A., et al. (2001). Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Research, 917(1), 97–104. doi:10.1016/S0006-8993(01)02926-2.
55. Shaw, P. J., Ince, P. G., Falkous, G., & Mantle, D. (1995). Oxidative damage to protein in sporadic motor neuron disease spinal cord. Annals of Neurology, 38(4), 691–695. doi:10.1002/ana.410380424.
56. Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A. C., Baik, M. J., MacGarvey, U., … Beal, M. F. (1997). Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of neurochemistry.
57. Robelin, L., & Gonzalez De Aguilar, J. L. (2014). Blood biomarkers for amyotrophic lateral sclerosis: Myth or reality? BioMed Research International, 2014. doi:10.1155/2014/525097.
58. Patel, B. P., & Hamadeh, M. J. (2009). Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clinical nutrition (Edinburgh, Scotland), 28(6), 604–617. doi:10.1016/j.clnu.2009.06.002.
59. Reinholz, M. M., Merkle, C. M., & Poduslo, J. F. (1999). Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Experimental Neurology, 159(1), 204–216. doi:10.1006/exnr.1999.7142.
60. Williams, J. R., Trias, E., Beilby, P. R., Lopez, N. I., Labut, E. M., Samuel Bradford, C., et al. (2016). Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the copper-chaperone-for-SOD. Neurobiology of Disease. doi:10.1016/j.nbd.2016.01.020.
61. Egawa, N., Kitaoka, S., Tsukita, K., Naitoh, M., Takahashi, K., Yamamoto, T., et al. (2012). Drug screening for ALS using patient-specific induced pluripotent stem cells. Science Translational Medicine, 4(145). doi:10.1126/scitranslmed.3004052.
62. Wainger, B. J., Kiskinis, E., Mellin, C., Wiskow, O., Han, S. S. W., Sandoe, J., et al. (2014). Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Reports, 7(1), 1–11. doi:10.1016/j.celrep.2014.03.019.
63. Kemp, K., Mallam, E., Hares, K., Witherick, J., Scolding, N., & Wilkins, A. (2011). Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts. PloS One, 6(10), e26098. doi:10.1371/journal.pone.0026098.
64. Dey, R., Kemp, K., Gray, E., Rice, C., Scolding, N., & Wilkins, A. (2012). Human mesenchymal stem cells increase anti-oxidant Defences in cells derived from patients with Friedreich’s ataxia. The Cerebellum, 861–871. doi:10.1007/s12311-012-0406-2.
65. Levy, O., Mortensen, L. J., Boquet, G., Tong, Z., Perrault, C., Benhamou, B., … Karp, J. M. (2015). A small-molecule screen for enhanced homing of systemically infused cells. Cell Reports, 1–8. doi:10.1016/j.celrep.2015.01.057.
66. Zeng, W., Xiao, J., Zheng, G., Xing, F., Tipoe, G. L., & Wang, X. (2015). Antioxidant treatment enhances human mesenchymal stem cell anti-stress ability and therapeutic efficacy in an acute liver failure model. Nature Publishing Group, 1–17. doi:10.1038/srep11100.